JOAQUIM PRADO PINTO DE MORAES FILHO
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Gastroenterologia, Faculdade de Medicina - Docente
5 resultados
Resultados de Busca
Agora exibindo 1 - 5 de 5
- Commentary: daily pantoprazole vs. esomeprazole for GERD - authors' reply(2014) MORAES-FILHO, J. P.; PEDROSO, M.; QUIGLEY, E. M. M.
- Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms(2014) MORAES-FILHO, J. P.; PEDROSO, M.; QUIGLEY, E. M. M.BackgroundPantoprazole magnesium (pantoprazole-Mg) may display extended inhibition of the proton pump with the potential for improved clinical efficacy in gastro-oesophageal reflux disease (GERD). AimTo compare the efficacy of pantoprazole-Mg and esomeprazole in GERD. MethodsGastro-oesophageal reflux disease (Los Angeles grades A-D) patients were randomised to 4weeks of treatment with pantoprazole-Mg (n=290) or esomeprazole (n=288), both 40mg once daily, in this multicentre (14 Brazilian sites in 9 cities), double-blind study, with an additional 4weeks' treatment in nonresponding patients. Severity of oesophagitis (at endoscopy) and GERD-related symptoms (ReQuest-GI) were assessed. The primary end point was the proportion of patients in complete remission (ReQuest-GI score <1.73 plus endoscopic healing) at week 4. ResultsComplete remission occurred in 61% of patients in each treatment group at 4weeks (primary endpoint) and in 81% and 79% of patients in the pantoprazole-Mg and esomeprazole groups at 8weeks, with no significant differences. Mucosal healing rates were high and not significantly different. At 8weeks, symptom relief with pantoprazole-Mg was significantly greater than that with esomeprazole (91.6% vs. 86.0%, P=0.0370) because of continued improvement in symptoms with pantoprazole-Mg from week 4 to week 8 (P=0.0206). ConclusionsPantoprazole-Mg 40mg was at least as effective as esomeprazole 40mg for complete remission and the mucosal healing rate was high. Symptom relief with pantoprazole-Mg continued to improve from 4 to 8weeks and was greater than that with esomeprazole at week 8, suggesting an extended period of treatment effect (ClinicalTrials.gov identifier: NCT01132638).
- Delayed Gastric Emptying of Semi-solid diets in Patients with Chagasic Megaesophagus(2014) CHINZON, Decio; NAVARRO-RODRIGUEZ, Tomas; DAL-PAZ, Karine; DIB, Ricardo Anuar; MORAES-FILHO, Joaquim Prado Pinto deOBJECTIVE: To measure the time to gastric emptying of a semi-solid diet in individuals with Chagasic megaesophagus, in comparison with a non-Chagasic control group. METHOD: The time to gastric emptying of a semi-solid diet was assessed via ultrasonography in 28 patients with Chagasic megaesophagus (grades I, II, and III) and compared to that of a control group (n = 15). After measurement of antral diameter under fasting conditions, 400mL of a semi-solid diet were administered and consecutive measurements were performed every 30 min. RESULTS: The duration of dysphagia was significantly lower in patients with megaesophagus grade I than in those with grades II or III. The time to gastric emptying was significantly increased in the megaesophagus group compared to the control group. The means of antral areas measured under fasting conditions and after maximal antral distension did not differ between the megaesophagus and control groups. CONCLUSION: The time to gastric emptying of a semi-solid diet was significantly greater in patients with Chagasic megaesophagus than in controls. The delay did not depend on the extent of dilatation of the megaesophagus or the duration of dysphagia.
- Noncompliance is an impact factor in the treatment of gastroesophageal reflux disease(2014) DOMINGUES, Gerson; MORAES-FILHO, Joaquim Prado P.The basis of pharmacological treatment of the gastroesophageal reflux disease is the use of proton pump inhibitors (PPIs) which provide effective gastric acid secretion blockade. However, PPI therapy failure may occur in up to 42% of patients. The main causes for therapeutic failure are non-acid or weakly acid reflux, genotypic differences, presence of comorbidities, wrong diagnosis and lack of treatment compliance. Noncompliance is an important issue and should be carefully observed. Several studies addressed patient compliance and 20-50% of patients may present lack of compliance to the PPI prescribed. When symptoms persist depite adherence has been confirmed, it is recommended to substitute the prescribed PPI to another of the same class or alternatively, prescription of a double dose of the same drug. When even so the symptoms persist, other causes of failure should be assigned. In particular cases of PPI failure, fundoplication surgery may be indicated.
conferenceObject Standard Triple Therapy for Helicobacter pylori Is Still the Best First Line Treatment in Brazil, Compared With Sequential Therapy: A Randomized, Prospective, Double-Blind, Placebo-Controlled Study(2014) EISIG, Jaime N.; NAVARRO-RODRIGUEZ, Tomas; TEIXEIRA, Ana Cristina; SILVA, Fernando M.; MATTAR, Rejane; CHINZON, Decio; MORAES-FILHO, Joaquim P.; HARO, Christiane; BARBUTI, Ricardo C.